Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJo, Helen E-
dc.contributor.authorCorte, Tamera J-
dc.contributor.authorGlaspole, Ian-
dc.contributor.authorGrainge, Christopher-
dc.contributor.authorHopkins, Peter M A-
dc.contributor.authorMoodley, Yuben-
dc.contributor.authorReynolds, Paul N-
dc.contributor.authorChapman, Sally-
dc.contributor.authorWalters, E Haydn-
dc.contributor.authorZappala, Christopher-
dc.contributor.authorAllan, Heather-
dc.contributor.authorKeir, Gregory J-
dc.contributor.authorCooper, Wendy A-
dc.contributor.authorMahar, Annabelle M-
dc.contributor.authorEllis, Samantha-
dc.contributor.authorMacansh, Sacha-
dc.contributor.authorGoh, Nicole S L-
dc.identifier.citationBMC Pulmonary Medicine 2019; 19(1): 84en_US
dc.description.abstractGastroesophageal reflux disease (GORD) is highly prevalent in idiopathic pulmonary fibrosis (IPF) and may play a role in its pathogenesis. Recent IPF treatment guidelines suggest that all patients with IPF be considered for antacid therapy. However, emerging evidence suggests that antacid therapy does not improve IPF patient outcomes and may increase the risk of pulmonary infection. Using prospectively collected data from the Australian IPF Registry including use of antacid therapy, GORD diagnosis and GORD symptoms, the relationship of these GORD variables to survival and disease progression was assessed. The severity of GORD symptoms using the frequency scale for symptoms of GORD (FSSG) and its relationships to outcomes was also assessed for the first time in an IPF cohort. Five hundred eighty-seven (86%) of the 684 patients in the Australian IPF Registry were eligible for inclusion. Patients were mostly male (69%), aged 71.0 ± 8.5 years with moderate disease (FVC 81.7 ± 21.5%; DLco 48.5 ± 16.4%). Most patients were taking antacids (n = 384; 65%), though fewer had a diagnosis of GORD (n = 243, 41.4%) and typical GORD symptoms were even less common (n = 171, 29.1%). The mean FSSG score was 8.39 ± 7.45 with 43% (n = 251) having a score > 8. Overall, there was no difference in survival or disease progression, regardless of antacid treatment, GORD diagnosis or GORD symptoms. Neither the use of antacid therapy nor the presence of GORD symptoms affects longer term outcomes in IPF patients. This contributes to the increasing evidence that antacid therapy may not be beneficial in IPF patients and that GORD directed therapy should be considered on an individual basis to treat the symptoms of reflux.en_US
dc.subjectGastroesophageal reflux diseaseen_US
dc.subjectIdiopathic pulmonary fibrosisen_US
dc.titleGastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleBMC Pulmonary Medicineen_US
dc.identifier.affiliationInstitute for Breathing and Sleepen_US
dc.identifier.affiliationSchool of Medicine, Western Sydney University, Sydney, NSW, Australiaen_US
dc.identifier.affiliationDepartment of Radiology, The Alfred Hospital, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationRespiratory and Sleep Medicineen_US
dc.identifier.affiliationDepartment of Respiratory Medicine, Royal Prince Alfred Hospital, Missenden Road, Camperdown, Sydney, NSW, 2050, Australiaen_US
dc.identifier.affiliationFaculty of Medicine, University of Sydney, Sydney, NSW, Australiaen_US
dc.identifier.affiliationNational Health and Medical Research Council Centre of Research Excellence in Pulmonary Fibrosis, University of Sydney, Sydney, NSW, Australiaen_US
dc.identifier.affiliationDepartment of Allergy and Respiratory Medicine, The Alfred Hospital, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationFaculty of Medicine, Monash University, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Respiratory Medicine, John Hunter Hospital, Newcastle, NSW, Australiaen_US
dc.identifier.affiliationSchool of Medicine, University of Queensland, Brisbane, QLD, Australiaen_US
dc.identifier.affiliationQueensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, QLD, Australiaen_US
dc.identifier.affiliationDepartment of Respiratory Medicine, Fiona Stanley Hospital, Perth, WA, Australiaen_US
dc.identifier.affiliationDepartment of Respiratory Medicine, Royal Adelaide Hospital, Adelaide, SA, Australiaen_US
dc.identifier.affiliationUniversity of Tasmania, Hobart, TAS, Australiaen_US
dc.identifier.affiliationDepartment of Thoracic Medicine, Royal Brisbane & Women's Hospital, Brisbane, QLD, Australiaen_US
dc.identifier.affiliationLung Foundation Australia, Brisbane, QLD, Australiaen_US
dc.identifier.affiliationDepartment of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, QLD, Australiaen_US
dc.identifier.affiliationTissue pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australiaen_US
dc.type.austinJournal Article-, Nicole S L
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.languageiso639-1en- and Sleep Medicine- for Breathing and Sleep-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jun 13, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.